As of 2026-03-28, the Relative Valuation of Royalty Pharma PLC (RPRX) is 30.60 USD. This relative valuation is based on P/E multiples. With the latest stock price at 46.35 USD, the upside of Royalty Pharma PLC based on Relative Valuation is -34.0%.
The range of the Relative Valuation is 24.94 - 35.37 USD.
| Range | Selected | |
| Trailing P/E multiples | 18.7x - 20.9x | 19.8x |
| Forward P/E multiples | 17.9x - 20.1x | 19.7x |
| Fair Price | 24.94 - 35.37 | 30.60 |
| Upside | -46.2% - -23.7% | -34.0% |
| Date | P/E |
| 2026-03-26 | 35.12 |
| 2026-03-25 | 35.19 |
| 2026-03-24 | 34.10 |
| 2026-03-23 | 34.13 |
| 2026-03-20 | 33.94 |
| 2026-03-19 | 34.07 |
| 2026-03-18 | 34.26 |
| 2026-03-17 | 34.50 |
| 2026-03-16 | 34.49 |
| 2026-03-13 | 34.16 |
| 2026-03-12 | 34.32 |
| 2026-03-11 | 34.94 |
| 2026-03-10 | 34.40 |
| 2026-03-09 | 34.30 |
| 2026-03-06 | 33.98 |
| 2026-03-05 | 34.18 |
| 2026-03-04 | 35.49 |
| 2026-03-03 | 35.53 |
| 2026-03-02 | 35.52 |
| 2026-02-27 | 34.58 |
| 2026-02-26 | 33.94 |
| 2026-02-25 | 33.78 |
| 2026-02-24 | 33.97 |
| 2026-02-23 | 34.02 |
| 2026-02-20 | 33.76 |
| 2026-02-19 | 33.75 |
| 2026-02-18 | 33.93 |
| 2026-02-17 | 33.98 |
| 2026-02-13 | 33.81 |
| 2026-02-12 | 33.52 |
| 2026-02-11 | 33.11 |
| 2026-02-10 | 33.08 |
| 2026-02-09 | 32.96 |
| 2026-02-06 | 33.41 |
| 2026-02-05 | 33.00 |
| 2026-02-04 | 32.68 |
| 2026-02-03 | 32.15 |
| 2026-02-02 | 31.70 |
| 2026-01-30 | 31.19 |
| 2026-01-29 | 30.57 |
| 2026-01-28 | 30.24 |
| 2026-01-27 | 30.48 |
| 2026-01-26 | 30.28 |
| 2026-01-23 | 30.23 |
| 2026-01-22 | 30.01 |
| 2026-01-21 | 29.72 |
| 2026-01-20 | 29.25 |
| 2026-01-16 | 29.59 |
| 2026-01-15 | 29.72 |
| 2026-01-14 | 30.09 |